Pharmacia settles Xalatan, Travatan patent cases
Executive Summary
Allergan will pay Pharmacia $120 mil. plus Lumigan product royalties "for a specified time" in Pharmacia Xalatan patent infringement suit settlement, Pharmacia says Oct. 25. Allergan will retain rights to worldwide commercialization of Lumigan. Allergan filed suit against Pharmacia March 1 seeking ruling that Lumigan did not infringe Xalatan patents (1"The Pink Sheet" March 19, p. 29). Pharmacia has also settled with Alcon over patent dispute involving Alcon's Travatan.Alcon will pay royalties on "past and future sales" of Travatan in return for continued unrestricted global marketing, Pharmacia says....
You may also be interested in...
Travatan and Lumigan Join Prostaglandin Class With March 16 Approval
Alcon's Travatan (travoprost) and Allergan's Lumigan (bimatoprost) are entering the prostaglandin analog class of glaucoma therapies following simultaneous approvals March 16.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.